To this end, we used previously developed peptide-oligonucleotide conjugate targeting PD-L1high tumor cells 22, in which an inhibitor of oncogenic miR-21 (anti-miR-21) was directly bound to a PD-L1-binding peptide (P21). The gene discussed is CD274; the disease is neoplasm.